A compound for use in a method of treating a homologous recombination (HR)-deficient cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: the bond - - - between X and Y is a single bond or a double bond; X and Y are independently selected from the group consisting of: O, N, CH, and C(=O); R 1 is selected from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 haloalkyl, C 6-12 aryl and 5-10 membered heteroaryl, each of which is optionally substituted by 1, 2, or 3 groups independently selected from the group consisting of: Cy 1 and R g ; R 2 and R 3 are independently selected from the group consisting of: H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 haloalkyl, C 1-6 alkoxy, and C 1-6 haloalkoxy; R 4 is selected from the group consisting of: H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 haloalkyl, C 6-12 aryl, and C 6-12 aryl-C 1-3 alkylene; R 5A and R 5B are independently selected from the group consisting of: H and C 1-3 alkyl; R 6A , R 6B and R 6C are independently selected from the group consisting of: OH, C 1-6 alkoxy, C 1-6 haloalkoxy, C(=O)NR a1 R a2 , and C(O)OR a1 ; R a1 and R a2 are independently selected from the group consisting of: H and C 1-3 alkyl; R 7 is selected from the group consisting of: H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 1-4 haloalkyl, each of which is optionally substituted by 1 or 2 Cy1; each Cy 1 is independently selected from the group consisting of: C 6-12 aryl and 5-10 membered heteroaryl, each of which is optionally substituted by 1, 2, or 3 independently selected R g groups; and each R g is independently selected from the group consisting of: OH, NO 2 , CN, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, amino, C 1-6 alkylamino and di(C 1-6 alkyl)amino. the bond - - - between X and Y is a single bond or a double bond; X and Y are independently selected from the group consisting of: O, N, CH, and C(=O); R 1 is selected from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 haloalkyl, C 6-12 aryl and 5-10 membered heteroaryl, each of which is optionally substituted by 1, 2, or 3 groups independently selected from the group consisting of: Cy 1 and R g ; R 2 and R 3 are independently selected from the group consisting of: H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 haloalkyl, C 1-6 alkoxy, and C 1-6 haloalkoxy; R 4 is selected from the group consisting of: H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 haloalkyl, C 6-12 aryl, and C 6-12 aryl-C 1-3 alkylene; R 5A and R 5B are independently selected from the group consisting of: H and C 1-3 alkyl; R 6A , R 6B and R 6C are independently selected from the group consisting of: OH, C 1-6 alkoxy, C 1-6 haloalkoxy, C(=O)NR a1 R a2 , and C(O)OR a1 ; R a1 and R a2 are independently selected from the group consisting of: H and C 1-3 alkyl; R 7 is selected from the group consisting of: H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 1-4 haloalkyl, each of which is optionally substituted by 1 or 2 Cy1; each Cy 1 is independently selected from the group consisting of: C 6-12 aryl and 5-10 membered heteroaryl, each of which is optionally substituted by 1, 2, or 3 independently selected R g groups; and each R g is independently selected from the group consisting of: OH, NO 2 , CN, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, amino, C 1-6 alkylamino and di(C 1-6 alkyl)amino. <EOS>